Jim Mazzola
Contacto de Relaciones con Inversores en OUTSET MEDICAL, INC. .
Perfil
Jim Mazzola is currently the Head-Investor Relations at Outset Medical, Inc. Prior to this, he worked as Senior Vice President-Communication at Cardinal Health, Inc. from 2003 to 2008.
He then served as Head-Communication at Halozyme Therapeutics, Inc. and as Senior Vice President-Corporate Marketing at CareFusion Corp.
from 2008 to 2015.
He also worked as Investor Contact at Turning Point Therapeutics, Inc. and as President at CareFusion Foundation.
Mr. Mazzola completed his undergraduate and MBA degrees from the University of Dayton.
Cargos activos de Jim Mazzola
| Empresas | Cargo | Inicio |
|---|---|---|
| OUTSET MEDICAL, INC. | Contacto de Relaciones con Inversores | 01/01/2022 |
Antiguos cargos conocidos de Jim Mazzola.
| Empresas | Cargo | Fin |
|---|---|---|
| CAREFUSION CORPORATION | Contacto de Relaciones con Inversores | 01/03/2015 |
| CARDINAL HEALTH, INC. | Public Communications Contact | 01/09/2008 |
| CareFusion Foundation | Presidente | - |
| HALOZYME THERAPEUTICS, INC. | Contacto de Relaciones con Inversores | - |
| TURG POIN | Contacto de Relaciones con Inversores | - |
Formación de Jim Mazzola.
| University of Dayton | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| CARDINAL HEALTH, INC. | Distribution Services |
| OUTSET MEDICAL, INC. | Health Technology |
| Empresas privadas | 3 |
|---|---|
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
CareFusion Corp.
 CareFusion Corp. Medical DistributorsDistribution Services CareFusion Corp. engages in the manufactures of medical equipment and device. The company was founded on February 4, 2009 and is headquartered in San Diego, CA. | Distribution Services |
| CareFusion Foundation |
- Bolsa de valores
- Insiders
- Jim Mazzola
